Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | IDE | P14735 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.51 |
| ▸ | HLCS | P50747 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5903487 | 1.00 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5903492 | 0.88 | TDP1 (0.55) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL15123570 | 0.86 | TDP1 (0.76) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL6036972 | 0.86 | TDP1 (0.76) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL19608935 | 0.85 | TDP1 (0.73) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22769195 | 0.85 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL19803917 | 0.84 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14563106 | 0.84 | PKM (0.49) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21422293 | 0.83 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14563108 | 0.83 | TDP1 (0.50) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301371-B2 | Cyclic monomer and dimer peptides having integrin antagonist activity | PROTAGONIST THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180105572-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | PROTAGONIST THERAPEUTICS, INC. | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301371-B2 | Cyclic monomer and dimer peptides having integrin antagonist activity | EPCAM, VCAM1, ICAM1 | TDP1 4657/4885MEN1 1000/4885ABL1 4167/4885 |
| US-20180105572-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | VCAM1, EPCAM, ICAM1 | TDP1 4727/4885MEN1 1257/4885ABL1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.